CORONA Remedies Board Approves FY26 Results, Recommends ₹10 Dividend
CORONA Remedies approved audited standalone and consolidated financial results for Q4FY26 and FY26. The board recommended a final dividend of ₹10 per share. M/s. Walker Chandiok & Co LLP was recommended as Statutory Auditors for five years. Dr. Kirtikumar Mehta's reappointment as Director and Chairman was also approved.
The approval of financial results and recommendation of dividend are material events for shareholders. The auditor appointments and director re-appointments are also significant corporate governance actions.
The company reported its financial results and recommended a dividend, indicating positive financial health and shareholder returns.
CORONA Remedies Limited announced the outcome of its Board Meeting held on May 11, 2026. The Board approved the Audited Standalone and Consolidated Financial Results for the fourth quarter and the year ended March 31, 2026, along with the respective Audit Reports. The auditors' reports on these financial results were unmodified.
Furthermore, the Board recommended a final dividend of ₹10 per equity share (100% of face value) for the financial year 2025-26, subject to shareholder approval at the ensuing Annual General Meeting (AGM). The company has fixed June 19, 2026, as the record date for determining entitlement to this dividend, which, if declared, will be paid on or before August 07, 2026.
In other key decisions, the Board approved the recommendation for the appointment of M/s. Walker Chandiok & Co LLP as Statutory Auditors for a five-year term from FY 2026-27 to FY 2030-31. M/s. Dhara Patel has been recommended as the Secretarial Auditor for five consecutive years starting from FY 2026-27. M/s. Shah & Shah Associates will be appointed as Internal Auditors for FY 2026-27, and M/s. Manish B. Analkat as Cost Auditor for FY 2026-27. Additionally, Dr. Kirtikumar Mehta's re-appointment as Non-Executive Director and Chairman for five years from April 01, 2027, was approved, pending shareholder approval.
The Board meeting commenced at 2:30 p.m. and concluded at 4:00 p.m.
What to do with a filing like this
CORONA Remedies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by CORONA Remedies Limited. Read the original for the full detail.